BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 10378673)

  • 1. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
    Focan C; Levi F; Kreutz F; Focan-Henrard D; Lobelle JP; Adam R; Dallemagne B; Jehaes C; Markiewicz S; Weerts J; Bismuth H; Jasmin C; Misset JL
    Anticancer Drugs; 1999 Apr; 10(4):385-92. PubMed ID: 10378673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
    Link KH; Kornmann M; Leder G; Pillasch AF; Sunelaitis E; Schatz M; Pressmar J; Beger HG
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):269-81. PubMed ID: 10065089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma.
    Lorenz M; Müller HH
    J Clin Oncol; 2000 Jan; 18(2):243-54. PubMed ID: 10637236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
    Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L
    J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): an effective treatment for metastatic colorectal carcinoma in the liver.
    Patt YZ; Mavligit GM; Chuang VP; Wallace S; Johnston S; Benjamin RS; Valdivieso M; Hersh EM
    Cancer; 1980 Jul; 46(2):261-5. PubMed ID: 6446376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases.
    Kemeny N; Conti JA; Sigurdson E; Cohen A; Seiter K; Lincer R; Niedzwiecki D; Botet J; Chapman D; Costa P
    Cancer; 1993 Mar; 71(6):1964-71. PubMed ID: 8443746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.
    Link KH; Pillasch J; Formentini A; Sunelaitis E; Leder G; Safi F; Kornmann M; Beger HG
    Eur J Surg Oncol; 1999 Aug; 25(4):381-8. PubMed ID: 10419708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
    Kerr DJ; Ledermann JA; McArdle CS; Buckels J; Neoptolemos J; Seymour M; Doughty J; Budden J; Taylor I
    J Clin Oncol; 1995 Dec; 13(12):2968-72. PubMed ID: 8523062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
    Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
    J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intra-arterial (5-FU/FA and FUDR) versus systemic chemotherapy (5-FU/FA) of non-resectable colorectal liver metastases].
    Gassel HJ; Müller HH; Mattes P; Stieger R; Schramm H; Lorenz M
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1458-60. PubMed ID: 9931911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update.
    Kemeny N; Seiter K; Conti JA; Cohen A; Bertino JR; Sigurdson ER; Botet J; Chapman D; Mazumdar M; Budd AJ
    Cancer; 1994 Feb; 73(4):1134-42. PubMed ID: 8313315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver.
    O'Connell MJ; Nagorney DM; Bernath AM; Schroeder G; Fitzgibbons RJ; Mailliard JA; Burch P; Bolton JS; Colon-Otero G; Krook JE
    J Clin Oncol; 1998 Jul; 16(7):2528-33. PubMed ID: 9667274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer.
    Stagg RJ; Venook AP; Chase JL; Lewis BJ; Warren RS; Roh M; Mulvihill SJ; Grobman BJ; Rayner AA; Hohn DC
    J Natl Cancer Inst; 1991 Mar; 83(6):423-8. PubMed ID: 1825674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
    Kelsen DP; Saltz L; Cohen AM; Yao TJ; Enker W; Tong W; Tao Y; Bertino JR
    Cancer; 1994 Oct; 74(8):2224-33. PubMed ID: 7922973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access.
    Copur MS; Capadano M; Lynch J; Goertzen T; McCowan T; Brand R; Tempero M
    J Clin Oncol; 2001 May; 19(9):2404-12. PubMed ID: 11331319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.
    Link KH; Sunelaitis E; Kornmann M; Schatz M; Gansauge F; Leder G; Formentini A; Staib L; Pillasch J; Beger HG
    Cancer; 2001 Dec; 92(11):2746-53. PubMed ID: 11753947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined 5-fluorouracil and floxuridine administered as a 14-day infusion. A phase I study.
    Anderson N; Lokich J; Bern M; Wallach S; Moore C; Williams D; Umprayn V
    Cancer; 1989 Mar; 63(5):825-7. PubMed ID: 2521571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial.
    Rougier P; Laplanche A; Huguier M; Hay JM; Ollivier JM; Escat J; Salmon R; Julien M; Roullet Audy JC; Gallot D
    J Clin Oncol; 1992 Jul; 10(7):1112-8. PubMed ID: 1296590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
    ; Piedbois P; Buyse M; Kemeny N; Rougier P; Carlson R; Allen-Mersh T; O'Connell M; Chang A; Sondak V; Kemeny M; Levy E
    J Natl Cancer Inst; 1996 Mar; 88(5):252-8. PubMed ID: 8614003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.
    Kemeny N; Gonen M; Sullivan D; Schwartz L; Benedetti F; Saltz L; Stockman J; Fong Y; Jarnagin W; Bertino J; Tong W; Paty P
    J Clin Oncol; 2001 May; 19(10):2687-95. PubMed ID: 11352961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.